Alpha 2.0
Login Register
» Journals » Mol Cancer Ther

Molecular Cancer Therapeutics

Molecular Cancer Therapeutics is a leading scientific journal that focuses on the latest advancements in cancer research and therapeutic strategies at the molecular level. It publishes cutting-edge studies on targeted therapies, drug development, and personalized medicine, providing valuable insights into the molecular mechanisms of cancer and potential treatments. This journal serves as a vital resource for researchers, clinicians, and pharmaceutical professionals working towards improving cancer treatment outcomes.
Details
Abbr. Mol Cancer Ther
Start 2001
End Continuing
Frequency Monthly
p-ISSN 1535-7163
e-ISSN 1538-8514
Country United States
Language English
Metrics
h-index / Ranks: 730 199
SJR / Ranks: 960 2270
CiteScore / Ranks: 1344 10.30
JIF / Ranks: 1231 5.7
Recent Articles
1.
Development of a novel bifunctional anti-CD47 fusion protein with improved efficacy and a favorable safety profile
Matar S, Skah S, Diomande L, Buss T, Hagland H, Yadav A, et al.
Mol Cancer Ther . 2025 Mar; PMID: 40084615
Therapeutic anti-CD47 monoclonal antibodies (mAbs) are designed to block the CD47-SIRPα checkpoint and promote immune-mediated recognition and elimination of cancer cells. However, current anti-CD47 mAbs have limitations, including off-tumor toxicity...
2.
A pharmacokinetic and pharmacodynamic model of an interleukin-12 (IL-12) anchored-drug conjugate for the treatment of solid tumors
Mistry H, Hodson D, Battula S, Schmidt M, Tighe R, Kaufman H, et al.
Mol Cancer Ther . 2025 Mar; PMID: 40079372
Interleukin-12 (IL-12) mediates innate and adaptive immune responses and has demonstrated therapeutic anti-tumor activity but clinical development has been hindered by a narrow therapeutic window. We generated a novel IL-12...
3.
hmLIGHT Enhances Vaccine Antitumor Effects by Facilitating T-cell Infiltration and Activation in the 4T1 Breast Cancer Model
Dong L, Zhang S, Wuri Q, Qu X, Zhang K, Cai Z, et al.
Mol Cancer Ther . 2025 Mar; :OF1-OF11. PMID: 40066767
Mounting evidence suggests that immunotherapies are promising strategies for fighting against cancers. However, the immunosuppressive tumor microenvironment (TME), insufficient lymphocytic infiltration, and poor immunogenicity hamper the broader implementation of immunotherapies....
4.
Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian Cancer
Cudmore A, Rodriguez G, Maranda V, Boroujeni S, Murshed H, Macdonald E, et al.
Mol Cancer Ther . 2025 Mar; PMID: 40062380
Epithelial Ovarian Cancer (EOC) is the most lethal gynecologic cancer and those affected are in urgent need of new therapeutic strategies. Standard treatment is surgery followed by taxane- and platinum-based...
5.
5'-S-(3-aminophenyl)-5'-thioadenosine, a novel chemoprotective agent for reducing toxic side effects of fluorouracil in treatment of MTAP-deficient cancers
Zhang S, Xue H, Wong N, Doerksen T, Ban F, Anderson S, et al.
Mol Cancer Ther . 2025 Mar; PMID: 40062378
Nucleobase analogue (NBA) drugs, such as 5-fluorouracil (5-FU), are effective chemotherapeutics, but their clinical use is limited by severe side effects. Compelling evidence suggests that the use of S-methyl-5'-thioadenosine (MTA)...
6.
177Lu-labeled antibody-drug conjugate: a dual mechanistic treatment modality in solid tumors
Yamaguchi A, Yamazaki C, Anami Y, Ha S, Xiong W, Ta R, et al.
Mol Cancer Ther . 2025 Mar; PMID: 40051166
To explore the potential of site-selectively radiolabeled antibody-drug conjugates (ADCs) against solid tumors, we constructed and evaluated radiolabeled ADCs equipped with lutetium-177 (177Lu) and a membrane permeable antimitotic agent. Site-selective...
7.
NOC2L promotes paclitaxel resistance in various types of ovarian cancers by decreasing NDUFA4 through histone acetylation suppression
Gu H, Qi S, Chen J, Wu H, Xu J, Feng Y
Mol Cancer Ther . 2025 Mar; PMID: 40036166
Ovarian cancer (OC) is a common malignant tumor in the female reproductive system. Paclitaxel resistance is the primary cause of treatment failure in patients with OC. Therefore, elucidating the mechanisms...
8.
PSMA-targeted Small Molecule-Drug Conjugates based on a Post-Prolyl Peptidase Cleavable Linker for the Treatment of Prostate Cancer
Georgiev T, Puglioli S, Principi L, Gilardoni E, Pellegrino C, Bassi G, et al.
Mol Cancer Ther . 2025 Mar; PMID: 40034039
Prostate Specific Membrane Antigen (PSMA) is a transmembrane glycoprotein that is over-expressed on the surface of cancerous prostate cells both in primary tumors and in metastases. Small organic ligands targeting...
9.
M4205 (IDRX-42) is a highly selective and potent inhibitor of relevant oncogenic driver and resistance variants of KIT in cancer
Esdar C, LInde N, Blum A, Schieferstein H, Drechsler C, Sherbetjian E, et al.
Mol Cancer Ther . 2025 Feb; PMID: 40018846
Primary activating mutations in KIT (exons 9/11) are key driver alterations in about 80% of gastrointestinal stromal tumors (GIST). Imatinib, a small molecule tyrosine kinase inhibitor, is used successfully as...
10.
Mechanisms Of Response And Resistance To PSMAXCD3 Bispecifics In CD34+ Humanized Mice
Mattson Cypert B, Menard K, Chu G, McDevitt T, Verona R, Rupnow B, et al.
Mol Cancer Ther . 2025 Feb; PMID: 40008870
Prostate cancer is considered immunologically "cold", with low mutational burden, tumor-infiltrating immune cells, and PD-L1 levels, culminating in poor response to immune checkpoint therapies. Bispecific CD3 redirection antibodies can elicit...